Tumor-Infiltrating Lymphocyte (TIL) Therapy

Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor microenvironment, where they recognize and target cancer cells. As a form of adoptive cell therapy, TILs can be harvested from a patient’s tumor, expanded ex vivo, and reinfused to promote immune-mediated tumor destruction. This approach leverages the body’s natural defense mechanisms and has shown promise in treating solid tumors, particularly in patients with limited responses to conventional therapies. Ongoing research continues to refine TIL-based strategies, optimizing their efficacy and integration into multidisciplinary cancer care.

The Association of Cancer Care Centers (ACCC) offers resources for TIL provider education and highlights best practices for improving care coordination between authorized treatment centers and community practices to enable timely referrals and access to treatment.